Immuneering (IMRX) Total Current Liabilities (2020 - 2026)
Immuneering (IMRX) posted quarterly Total Current Liabilities of $5.0 million for Q1 2026, down 2.62% year-over-year from $5.1 million in Q1 2025, and down 50.62% quarter-over-quarter from $10.1 million in Q4 2025.
Immuneering (IMRX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Immuneering's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 2.62% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (down 2.62% YoY), while the FY2025 annual figure was $10.1 million, up 34.25% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $5.0 million, down from $10.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $10.1 million in Q4 2025, with the low at $3.7 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $6.8 million (2024), against an average of $6.5 million.
- Peak annual rise in Total Current Liabilities reached 50.41% in 2023, while the deepest fall reached 22.51% in 2023.
- Immuneering's Total Current Liabilities stood at $8.1 million in 2022, then dropped by 2.59% to $7.8 million in 2023, then retreated by 4.36% to $7.5 million in 2024, then jumped by 34.25% to $10.1 million in 2025, then plunged by 50.62% to $5.0 million in 2026.
- Business Quant data shows IMRX's Total Current Liabilities at $5.0 million in Q1 2026, $10.1 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.12 Mn |
| Mar 31, 2026 | 4.97 Mn |
| Dec 31, 2025 | 10.07 Mn |
| Sep 30, 2025 | 9.55 Mn |
| Jun 30, 2025 | 7.49 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 7.50 Mn |
| Sep 30, 2024 | 6.92 Mn |
| Jun 30, 2024 | 6.78 Mn |
| Mar 31, 2024 | 5.18 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Sep 30, 2023 | 5.62 Mn |
| Jun 30, 2023 | 5.48 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | 7.26 Mn |
| Jun 30, 2022 | 3.80 Mn |
| Mar 31, 2022 | 3.67 Mn |
| Dec 31, 2021 | 5.63 Mn |
| Sep 30, 2021 | 5.27 Mn |